Somatostatin receptors in nasopharyngeal carcinoma

Published on Wednesday, 14 February 2018


Somatostatin receptors (SS-Rs) are expressed in neuroendocrine tumour tissues where they can be targetted for diagnosis and therapy.

This study investigated the presence of SS-Rs in nasopharyngeal carcinoma (NPC), a common cancer in South-East Asia.

Nasopharynx biopsy specimens were obtained from 12 NPC patients and 5 patients without tumours.

Somatostatin receptor autoradiography was performed using (125)I-labelled [Tyr(3)]-octreotide and (125)I-labelled [Leu(8), DTrp(22), Tyr(25)]-somatostatin-28 as radioligands.

Of the 12 NPC samples 9 showed moderate to high expression of SS-Rs. These were of the sst(2) type, based on the rank order of potency of subtype-selective analogues.

The 5 non-neoplastic samples, consisting primarily of granulomatous tissue, did not express measurable amounts of SS-Rs.

This study demonstrates for the first time the presence of type 2 SS-R in NPC.

These receptors may play a role in the management of NPC, as is the case for other somatostatin-expressing tumours.


About this publication.

See also:

- Somatostatin in oncology, the overlooked evidences;

- The Di Bella Method (A Fixed Part - Somatostatin, Octreotide, analogues and/or derivatives);

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.